What is the treatment for onychomycosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Onychomycosis (Fungal Toenail Infection)

Oral terbinafine 250 mg daily is the first-line treatment for onychomycosis: 12 weeks for toenails and 6 weeks for fingernails. 1, 2, 3

Understanding the Causative Organisms

The term "mold in toenails" refers to onychomycosis, which can be caused by three categories of fungi:

  • Dermatophytes (90-95% of cases): Trichophyton rubrum is the most common causative organism 4, 5
  • Yeasts: Primarily Candida albicans 4, 5
  • Nondermatophyte molds: Including Scopulariopsis, Aspergillus, Fusarium, and Acremonium 6

Treatment Algorithm Based on Pathogen

For Dermatophyte Infections (Most Common)

First-line: Terbinafine 1, 2

  • Dosage: 250 mg daily for 12 weeks (toenails) or 6 weeks (fingernails) 1, 2
  • Mechanism: Inhibits squalene epoxidase, directly fungicidal against dermatophytes 1, 2
  • Evidence level: Strength A, Level 1+ 2
  • Superior efficacy compared to all other oral agents 1, 2

Alternative: Itraconazole 1, 2

  • Dosage: 200 mg twice daily for 1 week per month (pulse therapy) 1, 2
  • Duration: 2 pulses for fingernails, 3 pulses for toenails 6, 1
  • Take with food for better absorption 1

For Candida Infections

First-line: Itraconazole 6

  • Dosage: 200 mg daily or 400 mg daily pulse therapy (1 week per month) 6
  • Duration: Minimum 4 weeks for fingernails, 12 weeks for toenails 6
  • Cure rates: 92% with pulse itraconazole versus 40% with pulse terbinafine 6

Alternative: Fluconazole 6

  • Dosage: 50 mg daily or 300 mg weekly 6
  • Use when itraconazole is contraindicated 6

For Nondermatophyte Molds (Difficult to Treat)

Preferred: Itraconazole 6

  • Broader antimicrobial coverage than terbinafine for molds 6
  • Aspergillus: Excellent susceptibility to itraconazole 6
  • Scopulariopsis: High cure rates (88%) with itraconazole 6
  • Standard regimen: 200-400 mg daily for 1 week per month for 3 months 6

Important caveat: Terbinafine demonstrates the lowest activity against most nondermatophyte molds despite being superior for dermatophytes 6

Topical Therapy (Limited Role)

Topical treatments should only be used in these specific scenarios 1, 7:

  • Superficial white onychomycosis
  • Very early distal infection (<80% nail involvement, no lunula involvement)
  • When oral therapy is contraindicated 1, 7

Topical options (if appropriate):

  • Amorolfine 5% nail lacquer: ~50% effectiveness when infection limited to distal nail 1, 7, 2
  • Ciclopirox 8% nail lacquer: 34% mycological cure versus 10% placebo 7, 2, 8
  • Efinaconazole 10% solution: FDA-approved, enhanced nail penetration 9

Special Populations

Diabetic Patients

Strongly prefer terbinafine over itraconazole 1, 7, 2

  • Lower risk of drug interactions and hypoglycemia 1, 7
  • Onychomycosis is a significant predictor for foot ulcers in diabetics 1, 2

Immunosuppressed Patients

Prefer terbinafine or fluconazole 1, 7

  • Lower risk of interactions with antiretrovirals and immunosuppressants 1, 7

Pediatric Patients

Pulse itraconazole therapy 6, 1

  • Dosage: 5 mg/kg/day for 1 week every month 6, 1
  • Duration: 2 months for fingernails, 3 months for toenails 6, 1

Alternative: Terbinafine daily 6, 1

  • <20 kg: 62.5 mg/day 1
  • 20-40 kg: 125 mg/day 1
  • 40 kg: 250 mg/day 1

  • Pediatric cure rates are higher (88-100%) than adults 6

Critical Pitfalls to Avoid

Always confirm diagnosis before treatment 7, 3

  • Use KOH preparation, fungal culture, or nail biopsy 3
  • Most common cause of treatment failure is incorrect diagnosis made on clinical grounds alone 7

Do not use topical therapy for extensive disease 7

  • Predictable failure when used inappropriately 7

Monitor for drug interactions 7, 4

  • Itraconazole: Potent CYP3A4 inhibitor 4
  • Terbinafine: Inhibits CYP2D6, monitor with SSRIs, beta blockers, tamoxifen 4, 10
  • Fluconazole: Inhibits CYP3A4, CYP2C9, CYP2C19 4

Expect treatment failures and recurrences 7, 2

  • Treatment failure rates: 20-30% even with best agents 7
  • Recurrence rates: 40-70% 1, 2

Prevention of Recurrence

Implement these strategies to reduce the 40-70% recurrence rate 1, 2:

  • Wear protective footwear in public facilities 1, 2
  • Use absorbent and antifungal powders in shoes 1, 2
  • Keep nails short 1, 2
  • Avoid sharing nail clippers 1, 2
  • Consider discarding contaminated footwear or treating with naphthalene mothballs 2

Second-Line Options (Avoid if Possible)

Griseofulvin: Only use when other agents unavailable or contraindicated 1, 2

  • Mycological cure rates: Only 30-40% 1, 2
  • Requires 12-18 months for toenails 1, 2
  • No efficacy demonstrated for Scopulariopsis 6

References

Guideline

Onychomycosis Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Onychomycosis Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Pharmacokinetics of antifungal agents in onychomycoses.

Clinical pharmacokinetics, 2001

Research

Onychomycosis.

Clinics in dermatology, 2010

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Onychomycosis Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Efinaconazole in Onychomycosis.

American journal of clinical dermatology, 2022

Research

Onychomycosis: Rapid Evidence Review.

American family physician, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.